| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615396 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 36 Pages |
Abstract
Our study revealed a higher prevalence of BRAF V600E mutation in Chinese MM patients. The associated prognostic impacts on younger patients could be beneficial to risk stratification and potential application of BRAF-targeted therapies in Chinese MM management. This is the first large-scale study revealing the prevalence and clinicopathologic significances of BRAF V600E mutation in Chinese myeloma.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Coty H.Y. Cheung, Chi Keung Cheng, Kin-Mang Lau, Rosalina K.L. Ip, Nelson C.N. Chan, Tommy H.C. Tam, Raymond S.M. Wong, Radha Raghupathy, Natalie P.H. Chan, Margaret H.L. Ng,